-
Je něco špatně v tomto záznamu ?
Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways
E. Jirkovsky, O. Popelová, P. Kriváková-Stanková, A. Vávrová, M. Hroch, P. Hasková, E. Brcáková-Dolezelová, S. Micuda, M. Adamcová, T. Simůnek, Z. Cervinková, V. Gersl, M. Sterba
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Open Access Digital Library
od 1997-01-01 do Před 1 rokem
ASPET Journals
od 1997 do 2013
PubMed
22915767
DOI
10.1124/jpet.112.198358
Knihovny.cz E-zdroje
- MeSH
- antracykliny toxicita MeSH
- buněčné jádro účinky léků metabolismus MeSH
- daunomycin farmakologie MeSH
- echokardiografie MeSH
- faktor 2 související s NF-E2 biosyntéza MeSH
- funkční vyšetření srdce MeSH
- glutathion metabolismus MeSH
- králíci MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- myokard patologie MeSH
- nemoci srdce chemicky indukované metabolismus MeSH
- oxidační stres účinky léků MeSH
- peroxidace lipidů účinky léků MeSH
- přežití MeSH
- protinádorová antibiotika toxicita MeSH
- srdeční komory účinky léků metabolismus MeSH
- srdeční mitochondrie účinky léků metabolismus MeSH
- transkripční faktory metabolismus MeSH
- troponin T metabolismus MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13012518
- 003
- CZ-PrNML
- 005
- 20130526185007.0
- 007
- ta
- 008
- 130404s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1124/jpet.112.198358 $2 doi
- 035 __
- $a (PubMed)22915767
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jirkovský, Eduard. $7 uk20201094982 $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, Hradec Králové, 500 38, Czech Republic.
- 245 10
- $a Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways / $c E. Jirkovsky, O. Popelová, P. Kriváková-Stanková, A. Vávrová, M. Hroch, P. Hasková, E. Brcáková-Dolezelová, S. Micuda, M. Adamcová, T. Simůnek, Z. Cervinková, V. Gersl, M. Sterba
- 520 9_
- $a Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antracykliny $x toxicita $7 D018943
- 650 _2
- $a protinádorová antibiotika $x toxicita $7 D000903
- 650 _2
- $a buněčné jádro $x účinky léků $x metabolismus $7 D002467
- 650 _2
- $a daunomycin $x farmakologie $7 D003630
- 650 _2
- $a echokardiografie $7 D004452
- 650 _2
- $a glutathion $x metabolismus $7 D005978
- 650 _2
- $a nemoci srdce $x chemicky indukované $x metabolismus $7 D006331
- 650 _2
- $a funkční vyšetření srdce $7 D006334
- 650 _2
- $a srdeční komory $x účinky léků $x metabolismus $7 D006352
- 650 _2
- $a peroxidace lipidů $x účinky léků $7 D015227
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a srdeční mitochondrie $x účinky léků $x metabolismus $7 D008929
- 650 _2
- $a myokard $x patologie $7 D009206
- 650 _2
- $a faktor 2 související s NF-E2 $x biosyntéza $7 D051267
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a králíci $7 D011817
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a přežití $7 D013534
- 650 _2
- $a transkripční faktory $x metabolismus $7 D014157
- 650 _2
- $a troponin T $x metabolismus $7 D020107
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Popelová, Olga. $7 _BN001885
- 700 1_
- $a Křiváková, Pavla, $d 1979- $7 stk2008428620
- 700 1#
- $a Vávrová, Anna. $7 _AN050099
- 700 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 700 1#
- $a Hašková, Pavlína. $7 xx0267424
- 700 1#
- $a Doleželová, Eva. $7 xx0179807
- 700 1_
- $a Mičuda, Stanislav, $d 1972- $7 jn20010309083
- 700 1_
- $a Adamcová, Michaela, $d 1964- $7 xx0064762
- 700 1_
- $a Šimůnek, Tomáš $7 xx0019029
- 700 1_
- $a Červinková, Zuzana, $d 1951- $7 nlk20020106444
- 700 1_
- $a Geršl, Vladimír, $d 1946-2015 $7 nlk19990073168
- 700 1_
- $a Sterba, Martin $u -
- 773 0_
- $w MED00002900 $t The Journal of pharmacology and experimental therapeutics $x 1521-0103 $g Roč. 343, č. 2 (2012), s. 468-78
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22915767 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130404 $b ABA008
- 991 __
- $a 20130526185358 $b ABA008
- 999 __
- $a ok $b bmc $g 975716 $s 810799
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 343 $c 2 $d 468-78 $i 1521-0103 $m The Journal of pharmacology and experimental therapeutics $n J Pharmacol Exp Ther $x MED00002900
- LZP __
- $a Pubmed-20130404